Teladoc Health (TDOC)
(Delayed Data from NYSE)
$13.01 USD
-0.32 (-2.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.97 -0.04 (-0.31%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
TDOC 13.01 -0.32(-2.40%)
Will TDOC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TDOC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TDOC
Teladoc (TDOC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
TDOC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for
Teladoc (TDOC) Increases Despite Market Slip: Here's What You Need to Know
Other News for TDOC
Teladoc: Huge Execution Problem
13 Analysts Assess Teladoc Health: What You Need To Know
Teladoc price target lowered by $1 at TD Cowen, here's why
Buy Rating Affirmed for Teladoc Amid Strong Quarterly Performance and Growth Potential
Teladoc price target lowered by $3 at Canaccord, here's why